Commonly-mutated genes have been found for many cancers, but less is known about 15 mutations in cis-regulatory elements. We leverage gains in tumor-specific enhancer activity, 16 coupled with allele-biased mutation detection from H3K27ac ChIP-seq data, to pinpoint potential 17 enhancer-activating mutations in colorectal cancer (CRC). Analysis of a genetically-diverse 18 cohort of CRC specimens revealed that microsatellite instable (MSI) samples have a high indel 19 rate within active enhancers. Enhancers with indels show evidence of positive selection, 20 increased target gene expression, and a subset is highly recurrent. The indels affect short 21 homopolymer tracts of A/T and increase affinity for FOX transcription factors. We further 22 demonstrate that signature mismatch-repair (MMR) mutations activate enhancers using a 23 xenograft tumor metastasis model, where mutations are induced naturally via CRISPR/Cas9 24 inactivation of MLH1 prior to tumor cell injection. Our results suggest that MMR signature 25 mutations activate or augment enhancers in CRC tumor epigenomes to provide a selective 26 advantage. 27 28 29
Introduction 30 31
In the past decade, tumor sequencing efforts by TCGA, ICGC, and others have identified the 32 most frequently mutated driver genes in most common forms of cancer (Lawrence et al. 2014; 33 Kandoth et al. 2013 ). Outside protein-coding genes, mutations in non-coding regions that 34 disrupt enhancer-gene control are emerging as a major mechanism of cancer development . 1 Examples include large chromosomal rearrangements that hijack enhancers to oncogenes, 2 such as the Burkitt lymphoma translocation that repositions IgH enhancers upstream of MYC 3 (Battey et al. 1983 ). Copy number alterations can amplify enhancer sequences near oncogenes . 4 Deletions can remove boundaries between enhancers and proto-oncogenes, and inversions can 5 flip enhancers to proto-oncogenes (Zhang et al. 2016; Beroukhim et al. 2016; Hnisz et al. 2016) . 6
Besides large structural variants that rewire gene-enhancer interactions, small-scale mutations 7 that lie within regulatory elements and alter their activity can occur. The first of these to be 8 discovered were recurrent point mutations in the TERT promoter in melanoma and other 9 cancers (Huang et al. 2013) . Other examples include a small indel that creates a super-10 enhancer that drives the overexpression of the TAL1 oncogene in T-ALL (Mansour et al. 2014) , 11 and recurrent enhancer substitutions and indels that affect the expression of PAX5 in CLL 12 (Puente et al. 2015) . The discovery of these driver events has motivated searches for additional 13 enhancer mutations in other common cancers, but so far their prevalence and relevance to the 14 cancer phenotype remain largely undetermined. 15
16
The identification of functional enhancer mutations is challenging due to several confounding 17 factors. First, mutation rates vary considerably between different tumor types and even among 18 tumors of the same subtype. Second, tumor epigenomes are heterogeneous and mutation rates 19 are profoundly influenced by chromatin states, with euchromatic early-replicating regions 20
showing a low mutation rate relative to heterochromatic late-replicating regions (Schuster-21 Böckler and Lehner 2012; Polak et al. 2015) . Given this variation, the conventional approach of 22 overlaying mutations detected through tumor sequencing with a "reference" epigenome is 23 suboptimal. Strategies that facilitate simultaneous capture of both sequence content and 24 regulatory activity are more suitable. Third and perhaps most importantly, for most cancers the 25 cell type of origin is unknown or unavailable for epigenomic studies. The lack of the normal 26 comparator makes it difficult to assess whether a putative mutation influenced the activity of the 27 regulatory element relative to the normal cell from which the tumor was derived. 28 
29
Through ChIP-seq analysis of enhancer histone marks (H3K4me1 and H3K27ac), we previously 30 compared the enhancer epigenomes of a genetically-diverse cohort of human CRC models to 31 normal colonic crypts, the cell type of origin for CRC. We identified Variant Enhancer Loci 32 (VELs) as sites that differed in the levels of H3K4me1 and H3K27ac between normal crypts and 33 each CRC sample (Akhtar-Zaidi et al. 2012; Cohen et al. 2017 ). Here, we pinpoint functional 34 enhancer mutations in VELs directly from H3K27ac ChIP-seq data, using the premise that a 1 DNA variant in an enhancer with higher H3K27ac levels in CRC than normal colon cells may 2 have contributed to the activation of that "gained" enhancer. Our analysis shows that CRC 3 samples with underlying deficiencies in mismatch-repair harbor an exceptionally high indel rate 4 in gained enhancers compared to their already high background mutation rate. We provide 5 evidence that these non-coding mutations, previously presumed to be inert, are functional. 6 7 8
Identification of putative enhancer activating indels 9 10 We looked for candidate mutations that augment enhancer activity by identifying somatic 11 mutations in regions with elevated levels of H3K27ac in CRC relative to normal colon ( Figure  12 1a). A key step in the analysis is identifying instances of allele bias, where H3K27ac ChIP-seq 13 read depth is higher on the allele containing the mutation than on the reference allele. We 14 further eliminate mutations that are not predictive of gained H3K27ac enrichment (i.e., the 15 mutation occurs in a cell line with the gained enhancer, but not in other cell lines with that same 16 enhancer), as these are more likely to represent passenger events. We focused on indels as 17 these have previously been shown to stimulate enhancer activation through de novo creation of 18 transcription factor binding sites (Mansour et al. 2014 ). Using H3K27ac ChIP-seq data from 24 19 cell lines derived from all clinical stages of CRC, we detected a total of 355 candidate enhancer-20 activating indels (example shown in Figure 1b ). Other signature features of enhancers were also 21 often present at these sites. Specifically, 85% (301/355) were located distal (>5 kb) to 22 transcription start sites (Figure 1c ), 76% overlapped H3K4me1 peaks, and 73% were located <1 23 kb from a DNaseI hypersensitive site. Nineteen out of 20 indels detected through our analysis 24 pipeline were validated through Sanger sequencing, indicating high specificity of our method 25 Microsatellite stable (MSS) samples harbored a lower enhancer mutation rate than MSI 30 samples, which are deficient in mismatch repair (MMR) genes: MLH1, MSH2, and PMS2. The 31 enhancer indels in MSI samples were predominantly short (1-2 bp) contractions of 32 homopolymer runs of T's and A's ( Figure 1e ), the classic mutational signature found in coding 33 regions of MSI tumors (Ionov et al. 1993; Kim et al. 2013 ). As expected, MLH1 and MSH2 34 deficient cell lines also showed higher indel rates than PMS2 deficient cells (Baross-Francis et 1 al. 2001; Hegan et al. 2006) . To further test the relevance of these findings, we analyzed 2 H3K27ac ChIP-seq data from 4 primary tumors (Cohen et al. 2017 ) of unknown microsatellite 3 status. One of the 4 samples, which was subsequently identified as the only MSI sample in the 4 group, showed an elevated enhancer mutation rate and the signature MSI mutation of poly A/T 5 homopolymers ( Figure 1-figure supplement 1c) . The results indicate that enhancer mutations 6 are prevalent in MSI-forms of CRC, and they show the same MMR signature as coding regions. 7
The presence of enhancer mutations in both cell lines and primary tumors rules out an in vitro-8 specific mechanism of enhancer activation. We reasoned that if an indel activated the enhancer, then gained enhancers would show a 22 higher proportion of allele-biased indels compared to enhancers that are already open, i.e, 23 enhancers shared between CRC and normal crypt. In all 5 MSI samples, the proportion of 24 allele-biased gained enhancers was higher than that of shared enhancers (Figure 2b ). Even 25 after controlling for enhancer length and H3K27ac signal intensity, gained enhancers were more 26 likely to contain allele-biased indels than shared enhancers (Figure 2c 
MSI enhancer mutations increase expression of cancer-related genes 31 32
We next tested the effect of the indels in gained enhancers on target gene expression. To 33 isolate the effect of the indel from that of the gained enhancer, we retrieved genes associated 34 with gained enhancer indels, and compared their expression in cell lines with both the indel and 1 the gained enhancer, to that of cell lines with only the gained enhancer. Genes regulated by 2 gained enhancers containing indels were more highly expressed than those same genes 3 regulated by gained enhancers containing the wildtype sequence ( Figure 3a , Figure 3 -source 4 data 1). We further verified that this expression difference was unlikely to be due to differences 5 in the levels of H3K27ac between the two test groups (Figure 3-figure supplement 1a ). In 6 further support of their functional relevance, genes with enhancer mutations were significantly 7 overexpressed in primary tumors ( Figure 3b ). The overexpressed genes had an over-8 representation of genes designated as "cancer-related" by the COSMIC database, or belonging 9 to known cancer pathways ( Figure 3c rates, suggesting that enhancer activation by indels occurs whenever a sufficiently high 2 mutation rate is reached. Furthermore, consistent with their positive selection, recurrent indels 3 occurred more frequently in gained enhancers than in enhancers shared between tumor and 4 normal crypts ( unbiased analysis revealed that MSI samples had 50% more gained enhancers at TGTTT(Tn) 1 sequences than MSS samples ( Figure 4f ). These observations indicate that gained enhancers 2 arise more frequently at the sequences most prone to mutation as a result of MMR-deficiency. 3
Coupled with the finding that these sites closely resemble the consensus motifs of FOX factors, 4 the computational prediction that the indels increase FOX affinity, and the ChIP-seq results 5
indicating allele-biased FOX binding to the indels, these observations suggest FOX factors play 6 an important role in mediating enhancer activation at the indels. We note however, that given 7 the degenerate nature of the FOX consensus motifs, our studies are limited in determining 8 which specific FOX factor(s) is responsible for the activation. in Figure 2a . Strikingly, we identified 45 indels in enhancers that showed at least a 1.5 fold 30 increase in the H3K27ac signal in MLH1 -/cells compared to parental wildtype cells (Figure 5e  31 shows an example). We compared the percentage of mutant-allele reads at the 45 gained 32 enhancer indels to that of the 1357 shared enhancer indels. Strikingly, the gained enhancer 33 indels were more often allele-biased ( Figure 5f ) suggesting the basis of enhancer activation was 34 acquisition of the indel. We further note that the frequency of indel-gained enhancer events 1 detected in this experiment is likely to be lower than in naturally-derived MSI tumors, since the 2 CRISPR-engineered cells spent a limited time in culture and were grown under conditions that 3 do not recapitulate selective pressures of the tumor microenvironment. To test if loss of MLH1 induces indels that activate enhancers in vivo, we introduced MLH1 9 knockout (clone 6e6-3) and wildtype (clone 1f12-2) cells into mice via intrasplenic injection 10 (workflow in summarized in Figure 6a ). In this assay, tumor cells typically form clonal liver 11 metastases, but are also known to form peritoneal tumors (Lee et al. 2014) . To simulate 12 different micro-environmental pressures, we used two mouse strains (nude and NSG) with 13 different levels of immune competence. Three months post-injection, 5 liver tumors were 14 harvested from mice seeded with MLH1 -/cells (4 tumors from one nude mouse and 1 tumor 15 from one NSG mouse). Two peritoneal tumors were harvested from one NSG mouse injected 16 with MLH1 +/+ cells. We then performed H3K27ac ChIP-seq profiling of all 7 tumors. 17
Unsupervised cluster analysis of the enhancer landscapes separated MLH1 +/+ from MLH1 -/-18 tumors, and there was remarkable consistency among tumors with matched genotypes (Figure  19 6b). Analysis of the mutations detected from H3K27ac ChIP-seq of the MLH1 -/tumors again 20 revealed predominantly small 1-2 bp deletions in mononucleotide tracts of A/T repeats ( Figure  21 6c, Figure 6 -source data 1). We also noted a shift in the proportion of non-homopolymer 22 mutations, including indels in larger tandem repeats and in non-tandem repeat regions. In each 23 MLH1 -/tumor, 6-10% of the indels were located in enhancers that showed at least a 1.5 fold 24 increase in the H3K27ac signal relative to wildtype tumor cells. Consistent with an enhancer-25 activating role, indels in gained peaks again showed higher mutant allele fractions compared to 26 indels in H3K27ac peaks already present at similar levels in the parental wildtype cells (Figure  27 6c, bottom). Using the ChIP-seq data from all 7 tumors, we identified 20 indels in MLH1 -/tumors 28 that showed a perfect correlation with an increase in H3K27ac, like the two examples shown in 29 Figure 6d . Strikingly, these 20 indels also showed high mutant allele fractions ( Figure 6e ). 30
Together, these data provide further functional support that MSI signature mutations activate 31 enhancers in vivo. way in which these mutations occur -led to allele-biased enhancer activation and selection of 20 enhancers both in cell culture and in full blown tumors, suggesting that the basis of enhancer 21 activation in these cells was acquisition of the mutation. Based on these findings, we conclude 22 that in CRC, deficiencies in mismatch repair lead to the appearance of indels that are 23 recognized by FOX factors, which turn these sites into functional cis-regulatory elements. It has 24 long been established that signature MMR-mutations, when they arise in coding regions, can 25 impact gene splicing or shift the reading frame. Indel mutations that induce a frameshift in 26 TGFBR2 are a notable example (Markowitz et al. 1995) . Our studies here expand the repertoire 27 of functional MSI-type mutations to non-coding regions, and offer a new method of identifying 28 functional mutations in regulatory elements. 29 30 There are notable differences between the functional regulatory mutations described here and 31 those previously linked to TERT, ER, TAL1, MYC, and FOXA1. The latter are considered tumor-32 initiating events and activate bona fide drivers of oncogenesis. In contrast, most of the enhancer 33 mutations reported here are a consequence of MMR-inactivation and likely arose subsequent to 34 mutations in canonical CRC drivers like APC, TP53, and KRAS. While some of the enhancer 1 indel targets could be oncogenes, most are genes with cancer-related functions that likely 2 provide a selective growth advantage. Another key difference is the high occurrence of 3 enhancer mutations in MSI CRC versus other cancers. Given their prevalence and widespread 4 effects on gene expression, MSI enhancer mutations could be considered "reprogrammers" of 5 cell identity. We further note, given that MSI is a continuously evolving phenotype, that 6 enhancer mutations due to MMR-deficiencies could play an important role in tumor evolution 7 and the emergence of drug resistance. Furthermore, as the MSI subset of CRC is a particularly 8 good candidate for immunotherapy, it would be worth investigating if enhancer mutations 9 instigate expression of PD-1 pathway genes or neoantigen-producing genes that contribute to 10 tumor immunogenicity and may therefore be exploited for refining response prediction. ChIP data processing, alignment, peak-calling, and identification of differentially enriched-peaks 20 relative to normal colonic crypts were done as previously described. to both reference and custom indel genomes was discarded. Samtools 1.2 was used to 28 generate a multi-way pileup output file for each filtered BAM. Indels were called using 29
VarScan.v2.4.0 from the pileup output, requiring at least 10X coverage and 20% of reads 30 supporting the indel. To exclude possible germline variants, indels matching dbSNPs from the 31 1000 Genomes Project and/or SNP142 indels were filtered out. 32
33
Candidate enhancer-activating mutations were prioritized based on whether they correlate with 1 gained H3K27ac enrichment. Binary matrices of indels and RPKM matrices were constructed 2 for all H3K27ac peaks. A peak was reported as correlating with an indel if the following 3 conditions were met: 4
1)
Peak RPKM for the sample the peak was called in is at least 2. 5
2)
Minimum peak RPKM for samples with indels in the peak is greater than the maximum 6 RPKM for the samples with no reported indels in the same peak. 7
3)
No reads support the indel in samples not called to have the indel 8 9
Indels were filtered if they overlapped artifact regions in the consensus Blacklist 10 (https://sites.google.com/site/anshulkundaje/projects/blacklists). An empirical approach was 11 used to identify indel calls that are likely alignment errors. For each indel, the sequence 50 bp 12 upstream and downstream was aligned to the human genome (Blat, from UCSC Genome 13 Browser). The reference allele was replaced with the indel allele, to simulate the alignment of 14 indel-supporting ChIP reads. Indels whose second-highest alignment score was > 50 indicated 15 potential alignment error and were discarded. RevertSam), but duplicate and alignment information was retained. Next, the alignment of reads 19 around indels was redone and then base quality scores were re-calibrated using GATK 20 IndelRealinger and BaseRecalibrator (version 3.2-2-gec30cee), respectively. Somatic 21 substitutions and indels were called using 2 mutation callers, MuTect2 (v3.5-0-g3628e4) and 22
Varscan2 (v2.3.9) using default settings, and the intersection of the calls was used for further 23 analysis. Variants in common dbSNP and in 1000 Genomes were filtered out as likely germline 24 events. Significance of the recurrence distribution was determined by randomly picking indels 25 (same number as actual recurrent indel set) from the binary matrix and finding the average 26 recurrence distribution of those random indels. 27 28
Transcription factor motif analysis. Ten products were run on a Genetic Analyzer ABI 3730 to produce fragment profiles, which were 28 visualized using Peak Scanner version 1.0 (ThermoFisher). 29 30 Mice. Two 6-week old female Nod-Scid IL-2Rg−/− (NSG) mice and two nude mice were each 31 injected intra-splenically with 10 6 (6e6-3 cells or 1f12-2) cells. After 3 months, mice were 32 sacrificed. Tumors were harvested and homogenized for H3K27ac ChIP-seq experiment. All V1051  V1009  V9P  V1058  V855  V456  V411  V400  V9M  V1106  V503  V389  V429  V1024  V1074  V576  V410  COLO205  SW480  V481  V703  HCT116 LoVo V457 CTTTGCTTTTCTCCACCCTGCGGGCAGTTAGCTTTTAAAG TTTTTTTTTTC  TTGCTTTTCTCCACCCTGCGGGCAGTTAGCTTTTAAAG TTTTTTTTTTCTT  CCACCCTGCGGGCAGTTAGCTTTTAAAG TTTTTTTTTTCTTTTAGAAGACT  CCTGCGGGCAGTTAGCTTTTAAAG TTTTTTTTTTCTTTTAGAAGACTTTTT  TGCGGGCAGTTAGCTTTTAAAG TTTTTTTTTTCTTTTAGAAGACTTTTTAC  GGGCAGTTAGCTTTTAAAG TTTTTTTTTTCTTTTAGAAGACTTTTTACTAG  GGGCAGTTAGCTTTTAAAG TTTTTTTTTTCTTTTAGAAGACTTTTTACTAG  CTTTTAAAG TTTTTTTTTTCTTTTAGAAGACTTTTTACTAGGCCACCCCC  TTTAAAG TTTTTTTTTTCTTTTAGAAGACTTTTTACTAGGCCACCCCCCCC  TTAAAG TTTTTTTTTTCTTTTAGAAGACTTTTTACTAGGCCACCCCCCCCC  TAAAG 
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